- Home
- NGS vs EDIT Comparison
NGS vs EDIT Comparison
Compare NGS & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NGS
- EDIT
- Stock Information
- Founded
- NGS 1998
- EDIT 2013
- Country
- NGS United States
- EDIT United States
- Employees
- NGS N/A
- EDIT N/A
- Industry
- NGS Oilfield Services/Equipment
- EDIT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NGS Energy
- EDIT Health Care
- Exchange
- NGS Nasdaq
- EDIT Nasdaq
- Market Cap
- NGS 328.4M
- EDIT 269.8M
- IPO Year
- NGS 2002
- EDIT 2016
- Fundamental
- Price
- NGS $27.84
- EDIT $3.08
- Analyst Decision
- NGS Strong Buy
- EDIT Buy
- Analyst Count
- NGS 3
- EDIT 11
- Target Price
- NGS $33.67
- EDIT $4.56
- AVG Volume (30 Days)
- NGS 44.0K
- EDIT 3.1M
- Earning Date
- NGS 11-10-2025
- EDIT 10-31-2025
- Dividend Yield
- NGS 1.44%
- EDIT N/A
- EPS Growth
- NGS 33.85
- EDIT N/A
- EPS
- NGS 1.42
- EDIT N/A
- Revenue
- NGS $164,109,000.00
- EDIT $38,901,000.00
- Revenue This Year
- NGS $9.86
- EDIT N/A
- Revenue Next Year
- NGS $14.21
- EDIT N/A
- P/E Ratio
- NGS $19.60
- EDIT N/A
- Revenue Growth
- NGS 14.77
- EDIT N/A
- 52 Week Low
- NGS $16.73
- EDIT $0.91
- 52 Week High
- NGS $29.74
- EDIT $4.54
- Technical
- Relative Strength Index (RSI)
- NGS 56.69
- EDIT 41.86
- Support Level
- NGS $27.05
- EDIT $2.94
- Resistance Level
- NGS $28.09
- EDIT $3.87
- Average True Range (ATR)
- NGS 0.82
- EDIT 0.32
- MACD
- NGS 0.09
- EDIT -0.13
- Stochastic Oscillator
- NGS 73.20
- EDIT 10.07
About NGS Natural Gas Services Group Inc.
Natural Gas Services Group Inc provides natural gas compression equipment and services to the energy industry. The company manufactures, fabricates, rents, sells, and maintains natural gas compressors and flare systems for oil and natural gas production and plant facilities. Its operating units include Rental, Sales, and Aftermarket services. The company generates the majority of its revenue by renting out low- to medium-horsepower compression equipment to natural gas production companies in unconventional oil and gas regions of the United States.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.